Weekly injection for weight loss and sleep apnea
Treatments studied
Part of Brain & nervous system, Hormones & metabolism, Lungs & breathing clinical trials.
This study tests a new once-a-week injection (called GZR18) to help people with obesity and sleep apnea lose weight and improve their breathing during sleep, without using a CPAP machine. The treatment may help you lose weight and reduce sleep apnea symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your body mass index (BMI) is 28 or higher (about 30 or more on a standard BMI scale).
- You have obstructive sleep apnea (OSA) but are not using a breathing device (like CPAP) and don't plan to start one during the study.
- You have tried to lose weight before with diet but it didn't work well enough.
- You do not have diabetes (except for past gestational diabetes during pregnancy).
- You have not had serious depression, recent suicidal thoughts, or certain heart/stomach conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing an investigational medication (GZR18) to help people with obesity and obstructive sleep apnea (a condition where breathing stops during sleep) lose weight. It is given alongside the usual positive airway pressure (PAP) therapy, which helps keep the airway open during sleep. The goal is to see if the drug can improve weight and possibly sleep apnea symptoms.
This trial tests an investigational weekly injection called XW003 for weight loss in people who have obesity and moderate-to-severe sleep apnea but do not use a CPAP machine. It aims to see if the drug can help with weight loss and improve sleep apnea without the need for a breathing machine.
This study tests an investigational injectable medication (HDM1005) to see if it can improve sleep apnea and help with weight loss in people who are obese and have obstructive sleep apnea but do not use a CPAP machine. The drug is given by injection and compared to a placebo.
This study tests a new injectable medicine for weight management in adults who are overweight. It aims to see how the medicine works in the body and how it affects weight.
This study is for people who finished a previous weight loss trial and want to continue treatment with an injectable medication GZR18. It tests how well the medicine works over a longer period.
This trial tests an injection called HRS9531 to see if it helps people with obstructive sleep apnea (OSA) and obesity who already use a CPAP or similar breathing device. It may help by reducing weight and improving breathing during sleep.
Hear when a new Obstructive Sleep Apnea (OSA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.